Previous close | 2.2000 |
Open | 2.2000 |
Bid | 0.4500 |
Ask | 4.5000 |
Strike | 28.00 |
Expiry date | 2024-05-17 |
Day's range | 2.2000 - 2.2000 |
Contract range | N/A |
Volume | |
Open interest | 13 |
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
PTC Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating